溢多利(300381) - 2020 Q4 - 年度财报

Financial Performance - The company's operating revenue for 2020 was CNY 1,914,764,458.88, a decrease of 6.51% compared to CNY 2,048,133,404.03 in 2019[15] - The net profit attributable to shareholders for 2020 was CNY 161,706,004.11, an increase of 26.81% from CNY 127,522,059.24 in 2019[15] - The net cash flow from operating activities was CNY 403,726,106.50, down 8.69% from CNY 442,165,361.20 in the previous year[15] - The basic earnings per share for 2020 was CNY 0.3471, reflecting a growth of 13.65% compared to CNY 0.3054 in 2019[15] - Total assets at the end of 2020 amounted to CNY 4,672,225,564.65, representing a 3.41% increase from CNY 4,518,083,187.45 in 2019[15] - The net assets attributable to shareholders increased by 20.80% to CNY 2,978,092,925.07 from CNY 2,465,213,969.38 in 2019[15] - The company reported a diluted earnings per share of CNY 0.3456, which is a 14.86% increase from CNY 0.3009 in 2019[15] - The weighted average return on net assets for 2020 was 5.94%, up from 5.63% in 2019[15] Revenue Breakdown - The revenue from steroid hormone raw materials accounted for 56.78% of total operating revenue, while the gross profit margin was 45.96%[52] - The revenue from bioenzyme preparations represented 29.02% of total operating revenue, with a gross profit margin of 34.94%[52] - Functional feed additives contributed 10.33% to total operating revenue, with a gross profit margin of 17.02%[52] - The biopharmaceutical sector generated CNY 1.09 billion, accounting for 56.78% of total revenue, down 9.92% from the previous year[55] - Revenue from the biological products sector increased by 9.01% to CNY 555.66 million, representing 29.02% of total revenue[55] - The functional feed additives segment saw a significant growth of 72.68%, with revenue reaching CNY 197.79 million[55] Investment and R&D - R&D expenses increased by 10.02% year-on-year, primarily due to the amortization of intangible assets from foreign technology introduction and increased salaries for R&D personnel[52] - The company is focusing on investment projects in biomedicine, enzyme preparations, and functional feed additives, supported by strong market demand and national policies[4] - The company plans to enhance its product offerings in the bio-pharmaceutical sector, including the development of new products such as fluocinolone and methylprednisolone[50] - The company is focusing on the research and development of antiviral drugs and related products[90] - The company has committed to invest RMB 20,000 million in the enzyme preparation project, with 99.80% of the investment completed by June 30, 2020[99] Market Expansion and Strategy - The company aims to expand its market presence by providing comprehensive biotechnology solutions and developing new products in response to industry demands[25] - The company is focusing on expanding its market presence through increased promotion of new products and optimizing the cost structure of existing products[30] - The company has established a comprehensive marketing network covering over 60 countries and regions, with more than 2,300 high-quality direct sales customers[44] - The company is actively pursuing mergers and acquisitions to strengthen its market position and expand its product offerings[101] - The company has strengthened its overseas market expansion efforts, conducting over 200 online meetings with international clients during the pandemic[49] Environmental Responsibility - The company is focused on improving its environmental performance and compliance with regulatory standards in its operations[181] - The company has a commitment to environmental protection, adhering to national standards for pollutant discharge[179] - The company has established a long-term management and supervision mechanism for environmental responsibility[151] - The company has achieved a desulfurization efficiency of 96% and a dust removal efficiency of 99% in its emissions control systems[191] - The company has a noise reduction strategy in place, utilizing sound-absorbing materials and centralized equipment to minimize environmental impact[188] Shareholder Returns - The company plans to distribute a cash dividend of CNY 0.7 per 10 shares, based on a total of 490,058,748 shares[4] - The cash dividend accounted for 100% of the total distributable profit of RMB 161,706,004.11[128] - The company maintained a consistent dividend policy over the past three years, with previous distributions of RMB 0.60 per share in 2018 and 2019[129] - The company’s profit distribution plan was approved by the board and independent directors, ensuring shareholder interests were protected[127] - In 2020, the cash dividend amount for the company was 34,304,112.36, representing 21.21% of the net profit attributable to ordinary shareholders[131] Compliance and Governance - The company has not faced any administrative penalties or criminal punishments related to the securities market in the past five years[135] - The company is committed to avoiding any illegal occupation of assets and ensuring fair market practices in related transactions[135] - The company has ongoing commitments regarding competition and related transactions, ensuring no direct or indirect competition with its business[132] - The company has established long-term business relationships with raw material processing enterprises and manufacturers in the US, Japan, India, and Germany, with over 80% of its sales coming from exports[112] - The company has received independent opinions from its independent directors and financial advisors regarding the use of fundraising for project adjustments and replacements[103]